Please use this identifier to cite or link to this item:
Appears in Collections:Psychology Journal Articles
Peer Review Status: Refereed
Title: Assessment of outcome in clinical trials in mild Alzheimer’s disease: Urgent time for a rethink?
Authors: Morrison, Yvonne
Wilson, J T Lindsay
Kelly, Fiona
Bennett, Crispin
Duffy, Fiona
McGoldrick, Susan
Reynish, Emma
Contact Email:
Issue Date: 1-Sep-2013
Publisher: OA Publishing London
Citation: Morrison Y, Wilson JTL, Kelly F, Bennett C, Duffy F, McGoldrick S & Reynish E (2013) Assessment of outcome in clinical trials in mild Alzheimer’s disease: Urgent time for a rethink?, OA Elderly Medicine, 1 (1), Art. No.: 3.
Abstract: Introduction: A major barrier for clinical trials in Alzheimer's disease is the lack of sensitive clinical endpoints for the early stages. Until recently, regulatory agencies have required demonstration of improvement in two disease domains, cognition plus functional or global status, as the evidence of symptomatic improvement during clinical trials for Alzheimer's disease. However, the model of Alzheimer's disease progression indicates impairment in cognition occurs earlier than changes in function and new draft guidance from the Food and Drug Administration considers change in cognition as an endpoint. The aim of this paper is to assess the outcomes of clinical trials in mild Alzheimer's disease. Short communication: The Alzheimer's disease assessment scale - cognitive subscale is the most widely used assessment of cognition in clinical trials; however, analysis of its psychometric properties, show it lacks the sensitivity to detect change in cognition in mild Alzheimer's disease. There is a need to develop a new outcome measure capable of capturing the subtle changes associated with mild AD in a reliable and valid way. Conclusion: Given the heterogeneity of AD phenotypes, development of a reliable, valid and clinically meaningful outcome measure is complex and challenging and will require discussion and cooperation between researchers, clinicians, industry and patients and their advocates to achieve success.
Type: Journal Article
Rights: Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY) Publisher is open-access. Open access publishing allows free access to and distribution of published articles where the author retains copyright of their work by employing a Creative Commons attribution licence. Proper attribution of authorship and correct citation details should be given.
Affiliation: The Clinical Trial Company Ltd
Dementia Studies
The Clinical Trial Company Ltd
The Clinical Trial Company Ltd
The Clinical Trial Company Ltd
Dementia Studies

Files in This Item:
File Description SizeFormat 
OA Elderly Medicine 2013.pdf147.19 kBAdobe PDFView/Open

This item is protected by original copyright

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

If you believe that any material held in STORRE infringes copyright, please contact providing details and we will remove the Work from public display in STORRE and investigate your claim.